Infrequent Reinfection after Successful Treatment for Hepatitis C Virus Infection in Injection Drug Users
Open Access
- 15 November 2004
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (10) , 1540-1543
- https://doi.org/10.1086/425361
Abstract
We followed-up 18 injection drug users for a mean of 33.8 months (range, 4–55 months) after successful treatment for hepatitis C virus (HCV) infection. Fifteen (83%) of the patients remained HCV RNA-negative, 1 patient was not tested, and 2 patients had test results positive for HCV RNA. The estimated rate of reinfection as a result of injection drug use was 0–4.1 cases per 100 person-years (cumulative incidence, 0%–12.6% at 48 months after completion of treatment). Of 50 patients originally treated, 15 (30%) were HCV RNA-negative 3 years later.Keywords
This publication has 37 references indexed in Scilit:
- Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapyGut, 2003
- National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10-12, 2002Hepatology, 2002
- Prevention and treatment of hepatitis C in injection drug usersHepatology, 2002
- Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2bClinical Therapeutics, 2002
- Interferontherapie während der EntzugsbehandlungSuchttherapie, 2002
- Hepatitis C infection and the patient with end-stage renal diseaseHepatology, 2002
- Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users?New England Journal of Medicine, 2001
- EASL International Consensus Conference on Hepatitis C Paris, 26–28 February 1999Journal of Hepatology, 1999
- Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspectsLiver International, 1995
- Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from FranceHepatology, 1991